MannKind (MNKD) Stock Rating Upgraded by BidaskClub

MannKind (NASDAQ:MNKD) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Wednesday.

A number of other research firms have also weighed in on MNKD. Maxim Group lowered shares of MannKind from a “hold” rating to a “sell” rating and set a $1.00 target price on the stock. in a report on Wednesday, February 28th. S&P Equity Research decreased their target price on shares of MannKind from $3.49 to $2.77 in a report on Thursday, January 25th. Zacks Investment Research lowered shares of MannKind from a “buy” rating to a “hold” rating in a report on Friday, April 6th. HC Wainwright set a $5.00 target price on shares of MannKind and gave the stock a “buy” rating in a report on Thursday, May 10th. Finally, ValuEngine raised shares of MannKind from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Four investment analysts have rated the stock with a sell rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $2.69.

MannKind opened at $1.99 on Wednesday, Marketbeat reports. The company has a debt-to-equity ratio of -0.43, a quick ratio of 0.39 and a current ratio of 0.43. The company has a market cap of $263.25 million, a P/E ratio of -1.72 and a beta of 2.92. MannKind has a 1-year low of $1.86 and a 1-year high of $1.91.

MannKind (NASDAQ:MNKD) last posted its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.02). The company had revenue of $3.47 million for the quarter, compared to analyst estimates of $3.53 million. During the same quarter in the previous year, the business earned ($0.17) earnings per share. research analysts expect that MannKind will post -0.83 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in MNKD. Bank of New York Mellon Corp grew its stake in MannKind by 30.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 108,380 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 25,125 shares in the last quarter. Wells Fargo & Company MN grew its stake in MannKind by 51.5% in the 3rd quarter. Wells Fargo & Company MN now owns 89,951 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 30,589 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in MannKind in the 3rd quarter worth approximately $270,000. Schwab Charles Investment Management Inc. grew its stake in MannKind by 60.5% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 188,428 shares of the biopharmaceutical company’s stock worth $438,000 after buying an additional 71,012 shares in the last quarter. Finally, Dupont Capital Management Corp grew its stake in MannKind by 99.9% in the 4th quarter. Dupont Capital Management Corp now owns 201,900 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 100,900 shares in the last quarter. 17.87% of the stock is owned by institutional investors and hedge funds.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit